• 1
    Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001;24:167202.
  • 2
    Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: Relationship to frontostriatal circuitry. Cogn Behav Neurol 2003;16:193210.
  • 3
    O’Connor MK, Boyle PA. Executive dysfunction in Alzheimer's disease. Res Prog Alzheimer's Dis Dementia 2007;1:2238.
  • 4
    Royall DR, Lauterbach EC, Cummings JL, et al. Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002;14:377405.
  • 5
    Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413421.
  • 6
    Farlow M, Cummings J. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:301308.
  • 7
    Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002; 127:619.
  • 8
    Braak H, Rub U, Jansen Steur EN, Del Tredici K, De Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:14041410.
  • 9
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:25092518.
  • 10
    Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:16541656.
  • 11
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:13561364.
  • 12
    Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22S32.
  • 13
    Smith A. Symbol digits modalities test manual. Los Angeles , CA : Western Psychological Services, 2000.
  • 14
    Delis D, Kaplan E, Kramer J. Delis-Kaplan executive function system, San Antonio , TX : Psychological Corporation, 2001.
  • 15
    Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008;64(Suppl 2):S81S92.
  • 16
    Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: A community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005;18:149154.
  • 17
    Owen AM. Cognitive dysfunction in Parkinson's disease: The role of frontostriatal circuitry. Neuroscientist 2004;10:525537.
  • 18
    Monchi O, Petrides M, Mejia-Constain B, Strafella AP. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007;130:233244.
  • 19
    Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A, Eidelberg D. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol 2006;28:11271144.
  • 20
    Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431438.
  • 21
    Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12:307323.
  • 22
    Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002;13:8387.